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Objectives This study sought to analyze the impact of new asymptomatic cerebral ischemic lesions,
found in diffusion-weighted magnetic resonance imaging (DW-MRI) after carotid artery stenting
(CAS) in relation to other risk factors for major adverse cerebral and cardiovascular events (MACCE)
deﬁned as death, stroke, and myocardial infarction.
Background After CAS, new cerebral lesions have been reported in up to 70% of patients. The im-
pact of asymptomatic lesions on prognosis after CAS has not been studied.
Methods Eight hundred thirty-seven consecutive patients underwent CAS with cerebral embolic
protection. In 728 patients (86.9%), a pre- and post-procedural DW-MRI was available; these patients
were included in the analyses. Multivariate Cox regression analysis and Kaplan-Meier estimates were
performed to identify independent risk factors for MACCE at follow-up. Clinical, procedural, and le-
sion characteristics and DW-MRI ﬁndings were included in the analyses.
Results Post-procedure new cerebral ischemic lesions were detected in 32.8% (n  241) of pa-
tients. Fifteen patients (1.79%) had a periprocedural MACCE and were therefore excluded from the
analysis. At a mean follow-up of 766.8  513.4 days (range 30 to 2,577 days), MACCE occurred in
45 patients (6.2%). Cox regression analysis and Kaplan-Meier estimates both identiﬁed diabetes as
the only signiﬁcant independent risk factor of MACCE. Asymptomatic cerebral lesions after CAS were
not associated with MACCE.
Conclusions Beyond 30 days, diabetes is the only risk factor of MACCE at follow-up. Asymptom-
atic cerebral embolic events after CAS had no prognostic impact. (J Am Coll Cardiol Intv 2013;
6:394–8) © 2013 by the American College of Cardiology Foundation
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395Diffusion-weighted magnetic resonance imaging (DW-
MRI) has been shown to be a sensitive tool in identifying
new ischemic cerebral lesions that are caused by emboli
during carotid artery stenting (CAS) (1–3). New lesions
have been reported in up to 70% of patients despite the
use of cerebral embolic protection devices (4 – 6). In
most patients, those lesions are not associated with
acute neurological symptoms. The impact of acutely
asymptomatic cerebral ischemic lesions on prognosis is
unknown.
We therefore studied the relevance of new asymptomatic
cerebral ischemic lesions in relation to other risk factors for
major adverse cerebral and cardiovascular events (MACCE)
(death, stroke, myocardial infarction) in a large cohort of
consecutive patients. Our hypothesis was that a positive
DW-MRI identifies a subgroup of patients with a more
advanced atherosclerotic disease and a higher risk of cerebral
and cardiovascular events at follow-up after a successfully
performed CAS.
Methods
Study population. In this retrospective study, 837 consecutive
patients underwent CAS with cerebral embolic protection
between February 2001 and December 2010. Of these pa-
tients, 728 had pre- and post-procedural DW-MRI available
and were included in the analyses.
Patients were eligible for CAS if they had a symptomatic
carotid artery stenosis 60% or an asymptomatic carotid
artery stenosis 80%.
The following clinical, lesion, and procedural character-
istics were recorded: age, sex, symptom status, diabetes
mellitus, hypertension, hyperlipidemia, uni- or bilateral
carotid artery stenosis, and aortic arch type. Lesion charac-
teristics included percent stenosis, lesion length, lesion
eccentricity, ulcerated lesions, thrombi-containing lesions,
and calcification. Procedural characteristics included dura-
tion of the CAS procedure and the use and type of embolic
protection.
Diffusion-weighted magnetic resonance imaging. Cerebral
DW-MRI scans were obtained on the day of the procedure
and 12 to 24 h after CAS using a 1.5-T Sonata Magnetom
scanner (Siemens, Erlangen, Germany). An independent
radiologist (A.W.) analyzed the DW-MRI for new isch-
emic lesions. Echo planar imaging with the following
parameters was used: TR 3,000 ms, TE 84 ms, 19 slices
with a slice thickness of 6 mm, field of view 230 mm,
diffusion values b  0, 500, 1,000 s/mm2, fat saturation,
ime of acquisition 71 s. Additionally, apparent diffusion
oefficient maps were obtained. A new lesion was defined as
focal hyperintense area detected by the fluid-attenuated
nversion recovery sequence, corresponding to a restricted
iffusion signal in the diffusion-weighted imaging sequence, tonfirmed by apparent diffusion coefficient mapping to rule
ut a shine-through artifact.
Procedure. Patients were on dual antiplatelet therapy (as-
irin 100 mg and clopidogrel 75 mg/day) before the
ntervention and for 4 weeks after. CAS with embolic
rotection was performed as described previously (7). Pa-
ients underwent neurological examination by an indepen-
ent neurologist before CAS and before discharge. Patients
ere monitored for at least 24 h. The first follow-up visit
ith neurological evaluation and duplex ultrasound of the
arget vessel was scheduled at 30 days.
Deﬁnitions. Patients were considered symptomatic if they
ad an ipsilateral neurological ischemic event within 6
onths before the procedure.
Diameter stenosis was determined angiographically ac-
ording to the NASCET (North American Symptomatic
arotid Endarterectomy Trial) criteria (8).
The degree of stenosis was calculated from the ratio of
he linear luminal diameter of the narrowest segment of the
iseased portion of the artery to the diameter of the artery
eyond any post-stenotic dilation.
Lesion calcification was de-
ned as positive if angiographi-
ally visible.
Ulceration was defined as the
xtension of contrast material
eyond the vascular lumen into
he surrounding plaque.
Lesion eccentricity was de-
ned as an eccentricity index
0.7. The maximal (A) and the
inimal wall thickness (B) were
easured. The eccentricity in-
ex was calculated using the following formula: (A  B)/A.
Thrombi-containing lesions were defined by angiography
s noncalcified filling defect outlined by contrast medium.
The type of the aortic arch was defined as described
reviously (9):
Type I, if the vertical distance from the origin of the
nnominate artery to the top of the arch is 1 diameter of
he left common carotid artery (CCA).
Type II, if vertical distance from the origin of the
nnominate artery to the top of the arch is between 1 and 2
eft CCA diameters.
Type III, if the vertical distance from the origin of the
nnominate artery to the top of the arch is 2 left CCA
iameters.
MACCE was defined as stroke, myocardial infarction,
nd death.
Stroke was defined as a new neurological deficit lasting
onger than 24 h.
Minor stroke corresponded to Rankin Scale grade 2 to 3
minor or moderate handicap; some or significant restric-
Abbreviations
and Acronyms
CAS  carotid artery
stenting
CCA  common carotid artery
DW-MRI  diffusion-
weighted magnetic
resonance imaging
MACCE  major adverse
cerebral and cardiovascular
eventsions in lifestyle), and major stroke corresponded to Rankin
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396Scale grade 4 to 5 (moderately severe or severe handicap;
precludes independent existence).
Statistical analyses. Continuous variables are reported as
mean  SD; discrete variables are reported as percentages.
Multivariate stepwise Cox regression analysis was per-
formed to identify independent predictors of adverse out-
comes at follow-up.
Univariate analyses with patient, procedural, and lesion
characteristics were performed. Factors entered into the
multivariate model included those with a p value 0.10
from the univariate analyses and new ischemic lesions in
DW-MRI. A p value 0.05 was considered statistically
significant. Survival curves were estimated by the Kaplan-
Meier method and compared by the log-rank test. Statistical
tests were performed using SPSS version 18.0 (IBM,
Armonk, New York) and GraphPad Prism version 3.00
(GraphPad Software, La Jolla, California).
Results
Patient and lesion characteristics. Between February 2001
and December 2010, 728 consecutive patients had pre- and
post-procedural DW-MRI and underwent carotid artery
stenting with embolic protection.
Patient’s characteristics are summarized in Table 1. The
mean age was 68.6  9.6 years, male 69.1%; 11.3% of the
patients were 80 years of age. A symptomatic stenosis was
present in 26.6% of the patients.
Lesion and procedural characteristics are shown in Table 2.
Mean percent stenosis of the target vessel was 86.2  7.5%,
mean lesion length was 15.4  5.3 mm, 82.8% of lesions
were eccentric, and 58.8% were calcified.
Embolic protection was used in 94.4% of patients.
DW-MRI ﬁndings. Of 837 consecutive patients, a cerebral
W-MRI was performed in 728 patients (86.9%) before
nd after CAS. Reasons for not performing a DW-MRI
ere contraindications for MRI (pacemaker, claustropho-
Table 1. Patient Characteristics
Age, yrs 68.6 9.6
80 yrs 82 (11.3)
Male 502 (69.1)
Asymptomatic stenosis 512 (70.3)
Symptomatic stenosis 191 (29.7)
Risk factors
Diabetes mellitus 22.5
Hypertension 88.4
Dyslipidemia 81.2
Aortic arch type
I 66 (22.5)
II 114 (38.9)
III 113 (38.5)Values are mean SD, n (%), or %.ia) or patient’s refusal. No patient had acute ischemic
esions in the pre-procedural DW-MRI. Post-procedure
ew cerebral ischemic lesions were detected in 32.8% (n 
41) of patients.
Thirty-day follow-up. At 30 days, all patients had a clinical
follow-up visit. The 30-day MACCE rate was 1.79% (n 
15). One patient died 2 days after CAS due to a hyperper-
fusion syndrome with massive intracerebral bleeding. Nine
patients sustained a minor, 5 patients a major stroke; none
of the patients had a myocardial infarction at 30 days. All 15
patients with a MACCE at 30 days were excluded from the
analyses because the purpose of the present study was to
evaluate the impact of asymptomatic cerebral ischemic
lesions after CAS.
Follow-up. Midterm follow-up was available for 89.8%
(n  654) of the patients and was performed either by a
patient visit or by telephone interview. The mean duration
of follow-up was 766.8  513.4 days (range 30 to 2,577
ays).
The MACCE rate was 6.2% (n 45). During follow-up,
34 patients died. Causes of death were cardiovascular in 10
patients, fatal stroke in 5 patients, and unknown in 19
patients. Ten patients sustained a stroke (5 minor and 5
major strokes), and 3 patients had a myocardial infarction.
The overall 2-year MACCE-free survival rate was 92.9%.
Risk factors for MACCE. Age, sex, symptom status, diabetes
mellitus, hypertension, hyperlipidemia, uni- or bilateral
carotid artery stenosis, aortic arch type, lesion characteristics
(including percent stenosis, lesion length, lesion eccentric-
ity, ulcerated lesions, thrombi-containing lesions, calcifica-
tion), and procedural characteristics (including duration of
CAS procedure, embolic protection, and the post-
procedural result of the DW-MRI) were entered into
univariate analyses.
In multivariate Cox regression analysis, diabetes mellitus
and the post-procedural result of the DW-MRI were
included.
Diabetes mellitus was the only independent risk factor of
MACCE during follow-up (hazard ratio: 3.3, 95% confi-
Table 2. Lesion and Procedural Characteristics
Internal carotid artery stenosis, % 86.2 7.4
Lesion length, mm 15.5 5.6
Eccentricity 83.1
Calciﬁed lesion 59.4
Ulcerated lesion 41.1
Thrombus-containing lesion 4.4
Duration of procedure, min 34.1 19.3
Embolic protection used 97.0
Filter 94.2
Occlusive protection 5.8
Values are mean SD or %.dence interval: 1.7 to 6.6, p  0.001). All the other clinical,
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397procedural, and lesion characteristics were not significantly
associated with MACCE. A positive DW-MRI after CAS
had no impact on long-term prognosis (hazard ratio: 1.2,
95% confidence interval: 0.6 to 2.5, p  0.65).
In support of the multivariate analysis, the Kaplan-Meier
analysis demonstrated that patients with diabetes had a
significantly higher incidence of MACCE after CAS (log-
rank test 18.67, p  0.0001) (Fig. 1).
Discussion
The major findings of the present study are:
1. Post-procedural asymptomatic cerebral lesions as as-
sessed by DW-MRI were found in 32.8% of patients.
2. The MACCE rate beyond 30 days at a mean
follow-up of 2.1 years was 7.2%.
3. Cox regression analyses and Kaplan-Meier estimates
revealed diabetes as the only predictor for MACCE
after CAS.
4. Asymptomatic cerebral lesions in DW-MRI after
CAS were not associated with MACCE during
follow-up.
The incidence of new ischemic lesions found in the present
study is well in accordance with what has been described in
the literature (4–6,10–13). Only 14 of 241 patients (5.8%)
with positive DW-MRI after CAS had a periprocedural
minor or major stroke; the remaining patients were neuro-
logically asymptomatic, as assessed by an independent
neurologist.
Whereas the periprocedural MACCE rate in the present
study is lower, the MACCE rate beyond 30 days is well in
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Figure 1. Kaplan-Meier MACCE-Free Survival
MACCE  major adverse cerebral and cardiovascular events.the range of what has been reported in randomized trials ofhigh- and intermediate-risk symptomatic and asymptomatic
patients (14–18).
Risk factors for periprocedural MACCE have been
identified in earlier studies, such as symptom status,
comorbidities, and unfavorable anatomical and lesion
characteristics (19 –21). By contrast, risk factors for
MACCE after the periprocedural period are not well
studied. Cremonesi et al. (21) found a significant differ-
ence in long-term survival of symptomatic versus asymp-
tomatic patients 79 years of age. Others have identified
low high-density lipoprotein cholesterol in combination
with elevated inflammatory markers as risk factors for
adverse long-term outcome after CAS (22). Diabetes was
not identified as a risk factor.
By contrast, in the present study of a large cohort of
consecutive patients, Cox regression analysis, as well as
Kaplan-Meier estimates, revealed diabetes mellitus as the
only independent risk factor.
To the best of our knowledge, this is the first study
analyzing the impact of asymptomatic cerebral ischemic
lesions after CAS on prognosis in terms of MACCE (death,
stroke, and myocardial infarction).
In the present study, a positive DW-MRI after CAS is
not an indicator for an increased risk of major adverse events
at follow-up. The same is true for other well-known risk
factors such as age, dyslipidemia, and hypertension. The
only indicator is diabetes, which indicates a more advanced
atherosclerotic disease and a higher risk of cerebral and
cardiovascular events (23).
The meaning of asymptomatic cerebral emboli during
CAS remains to be elucidated.
It has to be considered, for instance, that we did not
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398changes in the absence of stroke have been described after
cardiopulmonary bypass procedures and were strongly asso-
ciated with microembolic events (10,11). Others have found
that multiple emboli during carotid endarterectomy can
cause deteriorations in cognitive functions (12). Further
studies on the potential long-term effect of asymptomatic
cerebral embolic events should include a battery of neuro-
psychometric tests.
Clinical implications. Diabetes mellitus is a key risk factor of
MACCE in patients undergoing CAS. These patients need
intensive treatment and careful surveillance.
Study limitations. Although this is a large cohort of patients
with DW-MRI after CAS, it is a retrospective analysis.
Cerebral ischemic lesions were only qualitatively assessed,
not quantified. A DW-MRI was performed in most
(86.6%), but not in all patients. Follow-up ranged from 30
to 2,577 days, thus some patients had only a short
follow-up.
With a longer follow-up, other risk factors for MACCE
might have been identified.
The cause of death could not be identified in all patients.
Diabetic patients were not differentiated by insulin dependency.
Conclusions
Beyond 30 days, diabetes is the only risk factor of MACCE
at follow-up after CAS. Asymptomatic embolic events after
CAS, as assessed by DW-MRI, have no prognostic impact.
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